MAM
Enormous Brands brings Soumitra Patnekar on board to lead planning vertical
NEW DELHI: Enormous Brands, an independent creative agency, has roped in former BBH director of strategy Soumitra Patnekar as the head of its planning vertical. In this role, Patnekar will be based out of the company’s Mumbai office and will develop brand strategies, communications strategies, and conduct market researches for the company’s clients.
Enormous Brands managing partner- Ashish Khazanchi said, “I'm delighted to bring Soumitra on board as a part of the management team in Enormous. His experience in personal care and in automobiles is extremely rich and we're looking forward to building on that. Apart from advertising, he's spent a fair amount of time in consulting and in studying the length and breadth of the country's consuming audiences His insights and experiences from there are invaluable as are his perspectives on building businesses.”
Patnekar said, "I am excited to lead the strategy function at Enormous Brands along with Ashish and Ajay. Today, more than ever, I feel that brands need to have a distinctive voice and a consistent footprint across the media and tech landscape. My aim is to help build real, authentic brands rooted in our ethos thereby helping clients achieve/get the right value for their products and services.”
Patnekar brings with him 15 years of brand planning & consulting experience across agencies (BBH, Grey, Contract) and consulting firms (Future brands & Sideways). He has led the strategy on Global Brands Like Audi, Axe, ABnBev & DPA (Diamond Producers association) & Indian majors like Marico & Ferrero India. His work on Axe, & Fiat Punto has won multiple effectiveness awards in International forums like APAC Effies & IAA (International Advertising Association).
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
